AnaBios presents high-quality primary human liver cells for preclinical drug discovery
Get instant alerts when news breaks on your stocks. Claim your one week free trial for StreetInsider Premium here.
SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) — Today, AnaBios announced that it will begin supplying high-quality primary human liver cells to pharmaceutical, biotech and academic laboratories to further enhance research success preclinical on drug discovery.
Human livers are obtained from ethically consenting donors for research purposes. Hepatocytes are then isolated from the liver by AnaBios’ team of experts using a proprietary method. High-quality hepatocytes are an essential reagent for successful clinical development, with hepatocyte-based assays helping to define the absorption, distribution, metabolism, and excretion (ADME) profiles of new drugs. Moreover, primary human hepatocytes are essential to understand the potential hepatotoxicity of new therapies. With this new area of focus, AnaBios continues its mission to develop important new ex-vivo human models to improve drug discovery.
“AnaBios is delighted to provide high quality hepatocytes to the research community,” said Dr. Andre Ghetti, Chief Executive Officer of AnaBios. “We understand the importance of hepatocytes in drug discovery and are committed to leveraging our expertise in human tissue recovery and cell isolation to produce a variety of different donor lots to meet the needs of our clients.
AnaBios is pleased to announce Orlando Mendoza as Director of Business Development for the new liver cell business. Mendoza will help guide the company’s strategic growth plan in this important area of preclinical drug discovery. He joins AnaBios from Promethera Biosciences DBA Novabiosis, where he helped establish and grow their business for subsequent acquisition.
“AnaBios hepatocytes are unique in terms of batch diversity and volume, in addition to their quality,” Mendoza said. “I am extremely excited to help AnaBios become a leading provider of hepatocytes by working with our talented team of scientists to deliver a personalized end-user experience. »
Located in San Diego, California, AnaBios aims to establish the safety and efficacy of novel compounds through its advanced human-focused translational technologies. AnaBios primarily focuses on areas of high and unmet medical need, including heart disease, lung disease, CNS disorders, pain, and itching. As a preclinical CRO, AnaBios has the largest network of hospitals and transplant centers to obtain human tissue samples from ethically consented donors for ex-vivo To analyse. For more information about AnaBios, visit http://www.anabios.com.
CONTACT:Chris Mathes, Ph.D.Chief Commercial OfficerEmail: [email protected]
This content was published via the newswire.com press release distribution service.
Source: Ana Bios